A Clinical study to evaluate the Safety and efficacy of hyaluronic acid injection containing stromal vascular fraction extracted from adipose tissue of patients with enophthalmos

Start Date31 Jan 2025

Sponsor / Collaborator

Bundang CHA Hospital

CTRI/2024/11/077456

/ Not yet recruitingNot ApplicableIIT

Effectiveness of 0.1 percent Hyaluronic Acid with 0.2 percent Chlorhexidine Mouthrinse or 0.2 percent Chlorhexidine Mouthrinse alone as adjunct to scaling and root planing on clinical parameters and salivary aspartate aminotransferase marker in Periodontitis : A Prospective randomized observer blinded study - NIL

Start Date10 Dec 2024

Sponsor / Collaborator

Dr. Reddy's Laboratories Ltd.

IRCT20091012002576N49

/ RecruitingPhase 2/3IIT

Comparisons the effect of hyaluronic acid injection in prevention of adhesions after hysteroscopy septoplasty

Start Date22 Oct 2024

Sponsor / Collaborator

Tehran University of Medical Sciences

100 Clinical Results associated with Hyaluronic acid

100 Translational Medicine associated with Hyaluronic acid

100 Patents (Medical) associated with Hyaluronic acid

7,636

Literatures (Medical) associated with Hyaluronic acid

01 Feb 2026·BIOELECTROCHEMISTRY

Plasma jet and plasma treated aerosol induced permeation of reconstructed human epidermis

Article

Author: Gaetan-Zin, Septuce ; Maaroufi, Zeineb ; Vijayarangan, Vinodini ; Rouillard, Amaury ; Grillon, Catherine ; Robert, Eric ; Stancampiano, Augusto ; Dozias, Sébastien ; Escot-Bocanegra, Pablo

As plasma-treated liquids have many applications in plasma medicine, their cutaneous effects for cosmetic purposes are also considered as an alternative way to treat skin without the electric hazards and limitations correlated with the use of a direct plasma. Our previous work on human skin explants showed increased transdermal diffusion of cosmetic ingredients (caffeine, hyaluronic acid) after direct plasma treatment. Despite this proven efficacy, these protocols still face limitations dealing with toxicity, small treatment areas and uneven surface coverage. To overcome these limitations and broaden the scope of non-thermal-plasma-based technology for skin care, this study presents for the first time the development and assessment of a plasma aerosol device to nebulize plasma-treated liquids on skin models. This work demonstrates how plasma jet and plasma treated aerosol can temporarily enhance permeation in reconstructed human epidermis (RHE), using fluorescein as a probe, under safe plasma delivery conditions. Transepithelial electrical resistance measurements confirm the transient nature of the plasma-induced modulation, suggesting the possibility to control the duration of the enhanced permeation. Overall, the achieved results demonstrate the potential of plasma jet and plasma treated aerosol to safely control diffusion through skin for cosmetic and medical purposes.

01 Feb 2026·JOURNAL OF COLLOID AND INTERFACE SCIENCE

A dual-drug delivery hydrogel platform based on hollow calcium carbonate nanoparticles for enhanced multimodal tumor therapy

Article

Author: Li, Weibo ; Zhou, Jian ; Gong, Yi ; Qi, Qiang ; Zhao, Xiaofeng ; Li, Jin ; Wei, Haoyu ; Wang, Ting ; Yao, Haoge ; Wang, Hongdi

Multimodal cancer therapies that integrate gas and photodynamic approaches hold significant promise but are often limited by low drug loading rates, short treatment durations, and suboptimal overall therapeutic efficacy. In this study, we developed hollow calcium carbonate nanoparticles via a one-pot gas-diffusion approach, employing rational selection and concentration tuning of amino acid additives to regulate particle formation. Notably, by utilizing L-arginine as a regulating agent, we produced nanoparticles with a significant specific surface area of 197.96 m²/g. Subsequent PEGylated/liposomal surface modification endowed the nanoparticles with excellent biocompatibility and an impressive drug loading capacity of up to 28.8 % and 26.9 % for the nitric oxide donor L-arginine and the photosensitizer indocyanine green (ICG), respectively. The resulting drug-loaded hollow amorphous calcium carbonate nanoparticles (PCAI NPs) have shown effective synergistic treatment against tumors through multimodal therapy methods, including photodynamic therapy, nitric oxide gas therapy, photothermal therapy, and calcium overload-induced cytotoxicity. Furthermore, PCAI NPs were encapsulated in an injectable thermo-responsive hydrogel system composed of Pluronic F-127 and hyaluronic acid, creating a nano drug delivery system that enables sustained, prolonged, and localized drug release. This work presents a high-loading, multifunctional nanoplatform for enhanced and prolonged multimodal cancer therapy.

01 Jan 2026·Biomaterials advances

Injectable amino-modified poly-L-lactic acid microspheres/hyaluronic acid-based hydrogel composites for soft tissue fillers

Article

Author: Zhang, Mei ; Sun, Dahui ; Zhou, Xingyu ; Dang, Junbo ; Shen, Chen ; Zhao, Tianhao ; Hu, Ruibo ; Jiang, Junhui ; Lin, Tong

Soft tissue fillers have received much attention for the treatment of skin aging and the restoration of missing or excised soft volumes. However, the development of fillers with both safety and applicability remains a challenge. This study presented a synergistic composite filler comprising aldehyde-modified hyaluronic acid (OHA), hydrazide-modified hyaluronic acid (NHA), amino-modified poly-L-lactic acid microspheres (NPLLA), and antioxidant copper peptide. The hydrogel formed in situ via Schiff base reaction exhibited excellent mechanical properties and immediate filling effect. The amino-modified PLLA microspheres were less likely to agglomerate, avoiding the occurrence of adverse reactions and further enhancing the mechanical properties of the filler. The timed-release platform provided protection for copper peptide stability, scavenged reactive oxygen species during the fibrotic encapsulation phase, and synergistically promoted collagen deposition. In a nude mice skin aging model, hydrogels stimulated collagen production through the TGF-β/Smad signaling pathway with good long-term filler efficacy. Therefore, NPLLA microspheres/hyaluronic acid-based composite hydrogels exhibit great potential as injectable soft tissue fillers.

News (Medical) associated with Hyaluronic acid

02 Oct 2025

·www.einpresswire.com

Saya Biologics and Maxigen Biotech Inc announce strategic collaboration to introduce osteoarthritis treatments in Mexico

Alliance aims to democratize access to hyaluronic acid therapies, improving mobility and quality of life for patients in Mexico. This agreement marks a milestone in our commitment to transform joint health management in Mexico and broaden access to innovative therapies.” — Adrian Garcia, CEO of Saya Bio MEXICO, MEXICO, October 2, 2025 / EINPresswire.com / -- Saya Biologics (Saya Bio), a Mexican biopharmaceutical company committed to expanding patient access to innovative, high-quality, and affordable biological treatments, and Maxigen Biotech Inc. , an international company specializing in the development and manufacture of hyaluronic acid-based therapeutic solutions, announced a strategic agreement to launch a portfolio of osteoarthritis products to the Mexican market. Under the terms of the agreement, Saya Bio will be responsible for regulatory registration, commercialization, and distribution of the products within Mexico. Meanwhile, Maxigen Biotech Inc. will manufacture and supply the finished products, leveraging its advanced technology platforms and internationally recognized quality standards. “This collaboration represents a pivotal moment in our journey to revolutionize joint health management in Mexico,” said Adrian Garcia, CEO of Saya Bio. “With 1.5 million people affected by osteoarthritis in Mexico , there’s an urgent need for effective, accessible treatment options. By partnering with Maxigen Biotech Inc., we’re not just bringing products to market – we’re offering hope and mobility to patients who have been limited by joint pain. Their advanced hyaluronic acid formulations align perfectly with our mission to deliver innovative, cost-effective solutions that can significantly improve quality of life.” For her part, Flora Liu, Head of Global Business Center of Maxigen Biotech Inc., expressed great enthusiasm about partnering with Saya Bio to expand the reach of hyaluronic acid solutions in Latin America. “This alliance reflects our shared commitment to providing high-quality products that support mobility, joint health, and better patient outcomes” she said. Osteoarthritis ranks among the most prevalent joint diseases. According to the WHO, approximately 500 million people are affected globally by this condition . As a result, through this joint effort, both companies reinforce their vision of driving innovation and accessibility in joint therapies, contributing to the well-being of thousands of people in Mexico and laying the foundation for further expansion in the region. About Saya Biologics Saya Biologics is a Mexican biopharmaceutical company committed to transforming access to innovative, high-quality, and affordable biological treatments in Latin America. Focused on addressing the region’s most pressing therapeutic challenges, Saya Biologics is building a robust portfolio of biosimilars and advanced therapies in areas such as oncology, immunology, cardiometabolic diseases and bone health. With strategic investment in place, the company will launch its first commercial products in 2025, followed by as many as 15 more products in 2026. For more information, visit: https://www.saya.bio/ or our LinkedIn profile. About Maxigen Biotech Inc. Maxigen Biotech Inc. specializes in the development and manufacturing of hyaluronic acid-based therapeutic products with applications in orthopedics, aesthetic medicine, and ophthalmology. The company operates globally, with certified manufacturing facilities and strong R&D capabilities. For more information, visit: https://mbi-bio.com/es/ Press Contacts: ● Fernando Cornejo fernando@neuma.mx ● Brenda T. Conde brenda.torres@neuma.mx Fernando Cornejo Neuma +52 55 4493 3515 email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

29 Sep 2025

·www.prnewswire.com

Vascarta Announces Completion of Phase 1 Clinical Trial of VAS-101 for the Treatment of Osteoarthritis

SUMMIT, N.J., Sept. 29, 2025 /PRNewswire/ -- Vascarta Inc., a clinical-stage biopharmaceutical company advancing innovative treatments for pain and inflammation, announced today the successful completion of its phase 1 clinical trial evaluating VAS-101 (Vasceptor®) for the treatment of osteoarthritis (OA). The study was conducted at Clinical Research Australia in Perth under the direction of Principal Investigator Dr. Adrian Lopresti. Publication and/or presentation of the data is expected in the coming months. The 60-patient, randomized, double-blind, placebo-controlled trial evaluated VAS-101, a proprietary curcumin gel, applied topically every other day for 28 days. The primary objective was to assess the effects of VAS-101 on pain in adults with chronic knee OA. Secondary objectives included evaluating the therapy's impact on safety and tolerability, quality of life, daily function, and the use of analgesics. Dr. Lopresti commented: "When taken orally, curcumin is limited by low absorption, which reduces its therapeutic potential. In this study, VAS-101 administered topically demonstrated promising pain-relieving effects in people with knee osteoarthritis. These findings suggest that Vascarta's Vasporta™ transdermal technology may overcome the bioavailability challenges of oral curcumin, enabling rapid, localized pain relief at much lower doses." About VAS-101 Curcumin is a well-known natural compound with anti-inflammatory and analgesic properties, but its clinical utility has been constrained by poor oral bioavailability. VAS-101 is a highly concentrated, patented curcumin gel formulated using Vascarta's proprietary Vasporta™ transdermal delivery platform, designed to enhance both local and systemic bioavailability. Unmet Need in Knee Osteoarthritis According to the U.S. Centers for Disease Control and Prevention, approximately 21% of U.S. adults were diagnosed with arthritis between 2019 and 2021, with the knee being the most affected joint (World Health Organization). Current treatment options often progress from oral medications to invasive interventions such as intra-articular corticosteroids, hyaluronic acid, platelet-rich plasma, or ultimately, surgical knee replacement. There remains a significant unmet need for non-invasive, effective, and well-tolerated therapies that can provide pain relief for patients, particularly those who cannot tolerate long-term NSAID use. Leadership Perspective "Osteoarthritis is one of the most prevalent and disabling chronic conditions," said Dr. Richard Prince, Vascarta Chairman, CEO & President. "The completion of this Phase 1 trial marks an important milestone in the development of VAS-101 and supports our vision to deliver a safer, effective, and non-invasive alternative for millions of patients worldwide." About Vascarta Vascarta is a clinical-stage pharmaceutical company focused on innovative topical and transdermal delivery of therapeutics for inflammatory conditions, with lead programs in osteoarthritis and sickle cell disease. For more information about Vascarta's clinical programs, please contact: Dr. Richard Prince, Chairman, CEO & President – [email protected] Media Inquiries: David Hymson – [email protected] SOURCE Vascarta Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 1

19 Aug 2025

·www.globenewswire.com

Teleflex Announces the Launch of Barrigel™ Rectal Spacer in Japan as a Proven Safe and Effective Option to Minimize the Harmful Long-Term Side Effects of Prostate Radiation Therapy

Innovative hyaluronic acid technology delivers enhanced control and precision, significantly lowering the risk of rectal toxicity during prostate radiation treatment.1-4Initial cases have now been performed in Japan. WAYNE, Pa., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced Barrigel™ rectal spacer is now available for purchase in Japan, effective immediately following regulatory approval, insurance coverage acceptance and appropriate use criteria issuance by Japanese academic societies. First cases commenced earlier this month following the approval from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for Barrigel™ rectal spacer, the first and only sculptable non-animal stabilized hyaluronic acid (NASHA) rectal spacer proven to significantly reduce radiation that reaches the rectum during prostate radiation therapy.1,5,6,7“Japan commercialization represents a key milestone in our global expansion strategy for the Barrigel™ rectal spacer,” said Liam Kelly, Chairman, President and CEO of Teleflex. “This launch supports our mission to offer the next-generation, NASHA rectal spacer that enables precise, symmetrical placement1,2,7—providing physicians with effective and proven control over the shape and placement of the implant.8 We remain committed to making Barrigel™ rectal spacer the standard of care for men undergoing prostate cancer radiation therapy.” In 2022, prostate cancer was the most common cancer among men in Japan, with 104,318 new cases—accounting for 18 percent of all cancer diagnoses nationwide.9 Barrigel™ rectal spacer is indicated for prostate cancer patients with T1-T3b disease.5 A U.S. clinical study found that 98 percent of men who were treated with Barrigel™ rectal spacer met the primary endpoint of achieving at least a 25 percent reduction in radiation to the rectum.1 Patients who met the primary endpoint averaged an 85 percent reduction in rectal V54 Gy radiation to the rectum, and Barrigel™ rectal spacer is proven superior in the reduction of acute and long-term Grade 1+ GI toxicity at 3 and 6 months compared to control.1,6Yoshiko Inoue, Teleflex Managing Director, Japan, said with the launch of Barrigel™ rectal spacer in Japan, more men will have access to a solution that helps minimize the rectal side effects of prostate cancer radiation therapy.1 “We’re proud to support this important advancement and remain committed to educating healthcare professionals on the value of rectal spacing and its adoption throughout Japan,” she said. Beginning in late May, training took place in Chiba, Japan under the direction of Dr. Jun Itami, who is among the top radiation oncologists in the country. “Barrigel™ rectal spacer is unique in that it does not impose time constraints during injection and offers excellent visibility under ultrasound1-4. This allows physicians to monitor the injection in real time and place the required amount precisely1,7 where needed for each individual patient,” said Dr. Itami. “As a result, a reliable distance between the prostate and rectum can be maintained, enabling safer and more robust radiation therapy planning, representing a new standard in rectal protection during radiation therapy1.” About Barrigel™ Rectal SpacerBarrigel™ rectal spacer is the first and only hyaluronic acid rectal spacer that separates the prostate from the rectum to protect the rectum during radiation therapy treatment for prostate cancer.1 Barrigel™ rectal spacer is made from Non-Animal Stabilized Hyaluronic Acid (NASHA).5 Hyaluronic acid is a substance naturally present in the human body and is highly biocompatible and fully absorbable. NASHA has a proven history of safety and efficacy in a wide variety of medical applications in men, women and children worldwide.2,10 Barrigel™ rectal spacer has been proven to significantly reduce unwanted side effects from prostate cancer radiation therapy1 and is cleared for rectal spacing in the United States, Australia, Europe and Japan.11 Barrigel™ rectal spacer is indicated for prostate cancer patients with T1-T3b disease.5 For more information about Barrigel™ rectal spacer, please visit https://barrigel.com/hcp/barrigel-control-matters. Barrigel™ Rectal Spacer Important Safety InformationBarrigel™ rectal spacer is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and, in creating this space, it is the intent of Barrigel™ rectal spacer to reduce the radiation dose delivered to the anterior rectum. Barrigel™ rectal spacer is composed of biodegradable material and maintains space for the entire course of prostate radiotherapy treatment and is intended to be absorbed by the patient’s body over time.Barrigel™ rectal spacer should only be administered by qualified and properly trained physicians with experience in ultrasound guidance and injection techniques in the urogenital/pelvic area.As with any medical treatment, there are some risks involved with the use of Barrigel™ rectal spacer. Potential complications associated with the use of Barrigel™ rectal spacer include, but are not limited to: pain associated with Barrigel™ rectal spacer injection; needle penetration of the bladder, prostate, rectal wall, rectum, or urethra; injection of Barrigel™ rectal spacer into the bladder, prostate, rectal wall, rectum, urethra, or intravascularly; local inflammatory reactions; infection; urinary retention; rectal mucosal damage, ulcers, necrosis; bleeding; constipation; and rectal urgency. More information on indications, contraindications, warnings and instructions for use can be found in the Instructions For Use at www.barrigel.com. Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare. Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose. At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com. Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management’s current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. Teleflex, the Teleflex logo, Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. All other trademarks are the property of their respective owners. © 2025 Teleflex Incorporated. All rights reserved. *Study sponsored by Palette Life Sciences, now part of Teleflex** Data from the Barrigel Pivotal Study analyzed using the same methodology as the Fischer-Valuck study***Drs Gejerman, Chao, Lederer, and Orio are paid consultants of Palette Life Sciences, now part of Teleflex. References Mariados NF, Orio PF III, King MT et al. JAMA Oncol (2023).*Svatos M, Chell E, King MT et al. Med Phys (2024).*Gejerman G, Goldstein MM, Chao M et al. Pract Radiat Oncol (2023).***Williams J, Mc Millan K, Chao M et al. J Med Imag Radiat Sci (2022).Japan Injectable Gel Instructions for Use (2025)Data on file. As of 4/01/2025.King MT, Svatos M, Orio PF III et al. Pract Radiat Oncol (2023).*Fischer-Valuck BW, Chundury A, Gay H, Bosch W, Michalski J. Hydrogel spacer distribution within the perirectal space in patients undergoing radiotherapy for prostate cancer: Impact of spacer symmetry on rectal dose reduction and the clinical consequences of hydrogel infiltration into the rectal wall. Pract Radiat Oncol. 2017;7(3):195-202.**Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer.Restylane® celebrates 25 years of natural-looking results with its signature line of hyaluronic acid fillers. 2021.Data on file Teleflex. 2025 Contacts:TeleflexLawrence KeuschVice President, Investor Relations and Strategy Developmentinvestor.relations@teleflex.com610-948-2836 Media ContactGlenn SilverFINN Partners National Media Relations Specialistglenn.silver@finnpartners.com646-871-8485 APM1275

Radiation TherapyDrug Approval

100 Deals associated with Hyaluronic acid

External Link

KEGG	Wiki	ATC	Drug Bank
D08043	Hyaluronic acid	-	DB08818

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Osteoarthritis, Knee	Phase 2	-	-	01 Jun 2021
Alpha 1-Antitrypsin Deficiency	Phase 1	-	Actelion Pharmaceuticals Ltd.	-
Asthma	Phase 1	-	Actelion Pharmaceuticals Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03460158 (Pubmed \| Plast Reconstr Surg)	Phase 4	-	101	Restylane-L	fivuygckqu(jktdxuszya) = oirmerzsnt nyqvaigkdy (jqfglsbbch ) View more	Positive	01 Oct 2025
NCT03460158 (Pubmed \| Plast Reconstr Surg)	Phase 4	-	101	Restylane-L Lyft	fivuygckqu(jktdxuszya) = pavtlvldrp nyqvaigkdy (jqfglsbbch ) View more	Positive	01 Oct 2025
NCT03460158 (CTgov)	Phase 4	-	101	Restylane-L®	kmpqghwkrr(bkkazmbuvc) = pftcopegeu zjcelfdzvy (ofsxjxagwg, nhoorjspcf - fkkageqbro) View more	-	27 Sep 2024
P558 (EBMT2020)	Not Applicable	Hematopoietic stem cell transplantation	32	Hyaluronic Acid Bladder Instillation	iuafcxpnme(woebcithax) = pysvtuqahm suayqkgyxq (ljnfqpxzir ) View more	-	29 Aug 2020
P558 (EBMT2020)	Not Applicable	Hematopoietic stem cell transplantation	32	Intravesical Hyaluronic Acid (Conventional Measures (hyperhydration, transfusion support, vesical irrigation))	mzkkrgzext(anvdpdypfk) = eivdkggmbg wmvluivhpc (hkbznnxure )	-	29 Aug 2020
EULAR2015	Not Applicable	Osteoarthritis	120	Durolane®	lpytcssbjf(vjvbgvqoyt) = hebnaofvij wsoxgrqewx (kafutgvpce ) View more	Positive	10 Jun 2015
EULAR2015	Not Applicable	Osteoarthritis	120	Placebo	lpytcssbjf(vjvbgvqoyt) = rekerkryxz wsoxgrqewx (kafutgvpce ) View more	Positive	10 Jun 2015
ASCO_GU2012	Phase 2	-	-	Injection of hyaluronic acid (HA)	ehtogzgswm(vzdtmspbhz) = tlkcllnnws rlumhlygvi (mjlarzgqoh ) View more	-	10 Feb 2012
EULAR2006	Not Applicable	-	204	Suvenyl® (1A, 2.5ml:25mg)	ppijbjahrn(uzxerwepdn) = Severe adverse reactions were not seen kcejtjramy (pcsyeingjp )	Positive	21 Jun 2006

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis